

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

ESTIMATE

RRID:SCR_026090

Type: Tool

Proper Citation

ESTIMATE (RRID:SCR_026090)

Resource Information

URL: <https://github.com/oicr-gsi/ESTIMATE>

Proper Citation: ESTIMATE (RRID:SCR_026090)

Description: Software application provides researchers with scores for tumor purity, level of stromal cells present, and infiltration level of immune cells in tumor tissues based on expression data.

Resource Type: software application, source code, software resource

Keywords: scores, tumor purity, stromal cells, infiltration level, immune cells, tumor tissues, expression data,

Availability: Free, Available for download, Freely available,

Resource Name: ESTIMATE

Resource ID: SCR_026090

License: MIT license

Record Creation Time: 20241123T053252+0000

Record Last Update: 20260810T040923+0000

Ratings and Alerts

No rating or validation information has been found for ESTIMATE.

No alerts have been found for ESTIMATE.

Data and Source Information

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Huang KK, et al. (2026) Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence. *Cancer discovery*, 16(3), 497.

Gui S, et al. (2026) Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer. *Molecular & cellular proteomics : MCP*, 25(3), 101513.

Zhu Y, et al. (2026) Multi-omics exploration of hypoxia in gastric cancer. *World journal of surgical oncology*, 24(1).

Wang XX, et al. (2026) Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer. *Journal for immunotherapy of cancer*, 14(2).

Ma Z, et al. (2026) Elevated PTK6 expression is associated with tumor immune microenvironment remodeling and predicts poor prognosis in endometrial carcinoma. *Frontiers in medicine*, 13, 1842564.

Zhang W, et al. (2026) Unveiling the comorbidity hub: WT1 drives renal cancer progression in chronic kidney disease and confers sirolimus vulnerability. *Experimental and therapeutic medicine*, 32(2), 220.

Cao Z, et al. (2026) Study on the mechanism of PSENEN in modulating cisplatin resistance in NSCLC through stromal cell interactions. *International immunopharmacology*, 169, 116037.

Zhao W, et al. (2026) A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked. *Cancer discovery*, 16(3), 460.

Li S, et al. (2026) PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2667.

Liu Y, et al. (2025) Identification and Validation of Four Serum Biomarkers With Optimal Diagnostic and Prognostic Potential for Gastric Cancer Based on Machine Learning Algorithms. *Cancer medicine*, 14(6), e70659.

Li B, et al. (2025) A practical distribution pattern of ??-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. *Translational oncology*, 52, 102282.

Gao M, et al. (2025) Targeting the KLF5/PI3K/AKT axis as a therapeutic strategy to overcome neoadjuvant chemoresistance in colorectal cancer. *Frontiers in immunology*, 16, 1593639.

Da Y, et al. (2025) Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA. *Discover oncology*, 16(1), 2257.

Zhao W, et al. (2025) A prognostic signature for lung adenocarcinoma in people who have never smoked. *bioRxiv : the preprint server for biology*.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. *Cancer research communications*, 5(9), 1530.

Liu Z, et al. (2025) Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens. *Breast cancer research and treatment*.

Sveen A, et al. (2024) Evolutionary mode and timing of dissemination of high-grade serous carcinomas. *JCI insight*, 9(3).

Fan Z, et al. (2024) A transcriptome based molecular classification scheme for cholangiocarcinoma and subtype-derived prognostic biomarker. *Nature communications*, 15(1), 484.

Wu J, et al. (2024) Identification of disulfidptosis-related clusters and construction of a disulfidptosis-related gene prognostic signature in triple-negative breast cancer. *Heliyon*, 10(12), e33092.

Yu Y, et al. (2023) Construction of a CCL20-centered circadian-signature based prognostic model in cervical cancer. *Cancer cell international*, 23(1), 92.